Enveric Biosciences — Third Quarter 2026 Earnings Summary

Enveric Biosciences reported a net loss of $2.5 million for the third quarter ended September 30, 2026, with cash-on-hand totaling $5.6 million. The company advanced final IND-enabling activities for its lead candidate EB-003, a non-hallucinogenic neuroplastogenic therapeutic, supported by preclinical data showing brain penetration and a distinct activity profile compared to DMT. Recent in vitro studies confirmed favorable absorption and metabolic properties with a reduced potential for drug-drug interactions, while independent assays reinforced the compound's predicted non-hallucinogenic profile. Additionally, Enveric secured a U.S. patent allowance for next-generation non-hallucinogenic mescaline derivatives in its EVM401 series.